Company / Revenue
Spero Therapeutics, Inc. Revenue History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$48.0M
FY2025
5-year range
$9.3M / $103.8M
FY2021-FY2025
Trend
-53.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Revenue has fluctuated over the past 8 years, ranging from $335,000 in FY2018 to $104M in FY2024.
Based on SEC 10-K filings.
$48M in FY2025 with a 5-year CAGR of +21.5%.
Declined from $54M to $48M over the past 2 years.
Revenue over time
Growth rates
- 3-Year CAGR
- +38.0%
- 5-Year CAGR
- +21.5%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +21.5%, indicating consistent growth.
- In FY2025, revenue decreased 53.8% year-over-year.
- Peak revenue was recorded in FY2024.
- Lowest revenue in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $48.0M | -53.8% |
| FY2024 | $103.8M | +94.0% |
| FY2023 | $53.5M | +193.1% |
| FY2022 | $18.3M | +95.7% |
| FY2021 | $9.3M | -48.6% |
| FY2020 | $18.1M | +357.6% |
| FY2019 | $4.0M | +1083.9% |
| FY2018 | $335.0K | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026